Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
about
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial.Drug Repurposing for the Treatment of Acute Myeloid Leukemia.Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
P2860
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Eradication of minimal residua ...... ing alemtuzumab consolidation.
@en
Eradication of minimal residua ...... ing alemtuzumab consolidation.
@en-gb
type
label
Eradication of minimal residua ...... ing alemtuzumab consolidation.
@en
Eradication of minimal residua ...... ing alemtuzumab consolidation.
@en-gb
prefLabel
Eradication of minimal residua ...... ing alemtuzumab consolidation.
@en
Eradication of minimal residua ...... ing alemtuzumab consolidation.
@en-gb
P2093
P2860
P50
P921
P356
P6366
P1154
2-s2.0-85007489762
P1476
Eradication of minimal residua ...... ing alemtuzumab consolidation.
@en
P2093
Abraham M Varghese
Alexandra F Smith
Andy C Rawstron
Christopher Fegan
Christopher Pocock
Donald Milligan
George Follows
Helen McCarthy
NCRI CLL Sub-Group
Walter Gregory
P2860
P304
P356
10.1111/BJH.14342
P407
P5530
P577
2016-12-29T00:00:00Z
P6179
1049749641
P6366
2563872746